Cholangiocarcinoma

• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Not authorised
  2022-501463-40-00 5 "Locally Advanced or Metastatic Cholangiocarcinoma"
• A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known t … Recruiting
  2025-522613-26-00 7 2026-03-13 "Advanced Solid Cancers"
• FAPI-PET value for the initial screening of pancreatic and biliary cancers (FAPDIG Study) Recruiting
  2024-517270-23-00 4 2026-03-05
• Efficacy and safety of trifluridin/tipiracil in combination with nanoliposomal irinotecan as a second line therapy in patients with cholangi … Recruiting
  2024-517330-18-00 4 2025-10-02 "advanced, non resectable or metastatic cholangio- or gallbla"
• Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants with Locally Advanced or Metastatic Cholangiocarc … Recruiting
  2024-514261-19-00 9 2025-03-24 "Locally advanced, unresectable or metastatic cholangiocarcin"
• A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 I … Recruiting
  2024-515307-19-00 1 2025-03-24 "Advanced, or metastatic solid tumors with methylthioadenosin"
• Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting
  2023-509767-25-00 1 2024-11-07 "Advanced PRAME Positive Cancers"
• A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch … Recruiting
  2023-505660-11-00 5 2024-04-24 "Cholangiocarcinoma (LTT, 26.0)"
• FOENIX-CCA4 Recruiting
  2023-503665-39-00 4 2023-11-14 "Advanced cholangiocarcinoma"
• Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanc … Recruiting
  2024-518656-23-00 4 2023-09-01 "locally advanced cholangiocarcinoma"
• Master Protocol of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobilia … Recruitment ended
  2022-502317-29-00 4 2023-07-12 "Advanced Hepatobiliary Cancer"
• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Recruitment ended
  2022-501463-40-01 5 2023-05-03 "Locally Advanced or Metastatic Cholangiocarcinoma"
• Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) Recruitment ended
  2023-507405-34-00 5 2019-08-07 "First-line patients with advanced biliary tract cancers (BTC"
• Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and … Ended
  2024-517340-61-00 5 2024-11-19 "Patients after curative intent resection of cholangiocarcino"
• Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (Neo … Ended
  2024-515660-31-00 4 2023-06-27 "intrahepatic cholangiocarcinoma"
• A Study of SGN-B7H4V in Advanced Solid Tumors Ended
  2023-503389-22-00 1 2022-08-31 "Fallopian tube cancer"
• ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJ … Ended
  2024-511847-24-00 4 2022-05-23 "Biliary tract cancer"
• Tucatinib and trastuzumab in solid tumors with HER2 alterations Ended
  2024-511481-37-00 4 2021-07-12 "Previously Treated, Locally-Advanced Unresectable or Metasta"
• A Phase 1 Study of HMPL-306 in Locally Advanced Solid Tumors with IDH mutations Ended
  2024-516370-30-00 3 2021-02-09 "- Locally advanced or metastatic solid tumors - Cholangiocar"
• A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selecte … Ended
  2024-513915-28-00 3 2019-06-14 "Bladder cancer, Cholangiocarcinoma, Colorectal Cancer, Epith"
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06
• A study to assess the safety and anti-tumor activity of T cell therapy in subjects with advanced liver cancer or any other AFP expressing tu … Ended
  2024-514437-37-00 1 2018-02-22 "Advanced Hepatocellular Carcinoma (HCC) that is not amenable"
• LSTA1 Phase 2a basket trial in advanced solid tumors Ended
  2023-503740-14-00 4 "Head and neck cancer"

Showing 1–23 of 23 trials